Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 유혜현 | - |
dc.date.accessioned | 2019-04-16T04:38:35Z | - |
dc.date.available | 2019-04-16T04:38:35Z | - |
dc.date.issued | 2016-01 | - |
dc.identifier.citation | JOURNAL OF HYPERTENSION, v. 34, No. 1, Page. 156-162 | en_US |
dc.identifier.issn | 0263-6352 | - |
dc.identifier.issn | 1473-5598 | - |
dc.identifier.uri | https://journals.lww.com/jhypertension/Abstract/2016/01000/Effects_of_orally_administered_antibiotics_on_the.22.aspx | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/102073 | - |
dc.description.abstract | Background: Amlodipine is a representative calcium channel blocker that is frequently prescribed for the treatment of hypertension. In this study, the possibility of drug-drug interactions between amlodipine and coadministered antibiotics (ampicillin) was investigated in rats; thus, changes in the metabolic activities of gut microflora and the consequent pharmacokinetic pattern of amlodipine following ampicillin treatment were characterized. Methods and results: In human and rat fecalase incubation samples, amlodipine was metabolized to yield a major pyridine metabolite. The remaining amlodipine decreased and the formation of pyridine metabolite increased with incubation time, indicating the involvement of gut microbiota in the metabolism of amlodipine. Pharmacokinetic analyses showed that systemic exposure of amlodipine was significantly elevated in antibiotic-treated rats compared with controls. Conclusion: These results showed that antibiotic intake might increase the bioavailability of amlodipine by suppressing gut microbial metabolic activities, which could be followed by changes in therapeutic potency. Therefore, coadministration of amlodipine with antibiotics requires caution and clinical monitoring. | en_US |
dc.description.sponsorship | This research was supported by a grant from Ministry of Food and Drug Safety in 2013 (12182MFDS652) and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry (NRF-2014R1A1A1A05002840). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | en_US |
dc.subject | amlodipine | en_US |
dc.subject | antibiotics | en_US |
dc.subject | bioavailability | en_US |
dc.subject | gut microbiota | en_US |
dc.subject | metabolism | en_US |
dc.subject | CALCIUM-ANTAGONIST AMLODIPINE | en_US |
dc.subject | DOSE-RESPONSE RELATIONSHIP | en_US |
dc.subject | DOUBLE-BLIND EVALUATION | en_US |
dc.subject | HUMAN PLASMA | en_US |
dc.subject | HYPERTENSION | en_US |
dc.subject | METABOLISM | en_US |
dc.subject | PHARMACOKINETICS | en_US |
dc.subject | QUANTIFICATION | en_US |
dc.subject | RAT | en_US |
dc.title | Effects of orally administered antibiotics on the bioavailability of amlodipine: gutmicrobiota-mediated drug interaction | en_US |
dc.type | Article | en_US |
dc.relation.no | 1 | - |
dc.relation.volume | 34 | - |
dc.identifier.doi | 10.1097/HJH.0000000000000773 | - |
dc.relation.page | 156-162 | - |
dc.relation.journal | JOURNAL OF HYPERTENSION | - |
dc.contributor.googleauthor | Yoo, Hye Hyun | - |
dc.contributor.googleauthor | Kim, In Sook | - |
dc.contributor.googleauthor | Yoo, Dae-Hyeong | - |
dc.contributor.googleauthor | Kim, Dong-Hyun | - |
dc.relation.code | 2016001260 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | yoohh | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.